Actavis and Warner Chilcott are exploring options for a merger after Actavis failed to merge with Valeant.
Healthcare Health/Fitness
Tokai Pharma Signs US$35.5M in Series E
Tokai Pharma receives US$35.5 series E capital financing round. Tokai Pharmaceuticals, Inc announced today that it was able to secure US$35. 5 million in a round of Series E growth financing in order to persuade investors to support Tokai's lead prostate cancer pharmaceutical product currently in medical development.
Cipla Medpro Shareholders Approve Deal
A near unanimous vote of Cipla Medpro shareholders approved the tender offer by Cipla Ltd. Cipla Medpro of South Africa shareholders voted for the approval of US$488 million takeover bid from Cipla Ltd of India.
Actavis Rejects Mylan Bid
The latest Actavis bid for Mylan has been rejected. In its latest move, Actavis had rejected the takover bid from Mylan last week. The bid was priced at US$15 billion, according to Reuters quoting an anonymous source familiar with the decision.
Lanx Concludes Series C with US$15M
Lanx Inc Concludes Series C funding by raising US$15 million. The privately held world renowned spine company, Lanx, Inc. disclosed today the conclusion of its Series C equity financing round by raising US$15 million.
Latest News
Quintiles IPO sells US$947 million to pay off debts and other corporate activities. Pharmaceutical support firm Quintiles Transnational Holdings has raised US$947 million for its IPO.
Canopus and Transentia joined by Alacrita to form a new company. The consulting firm on transatlantic life science, Alacrita combined the expertise of two consulting firms on life science performance and named Dr.
Takeda purchases Inviragen for a total of US$250 million. In a joint statement of Inviragen, Inc and Takeda Pharmaceutical Company Limited, it disclosed that Takeda's fully owned company,Takeda America Holdings, Inc, have entered into a final acquisition agreement.
Berkshire Hathaway increases shareholdings in DaVita Health Care. Berkshire Hathaway, the largest investor in DaVita Health Care Partners Inc, has entered into an agreement to increase its shareholdings to 25% of the US operator of dialysis clinics.
Neurophage receives US$6.4 million as investment capital. NeuroPhage disclosed in an announcement that it was able to accumulate a US$6. 4 million from its round of private equity growth fund.
Medifox Group to grow with ECM Equity at the helm. On Tuesday, German Equity Partners IV, a fund administered by the independent German private equity firm, ECM Equity Capital Management GmbH has purchased MediFox Group.
Series B fundraiser saw STAT-Diagnostica raise US$22.1 million. STAT-Diagnostica disclosed the conclusion of its Series B growth financing round that earned an estimated amount of US$22 million or EUR17 million.
Virtus expects a price per share between Aus$4.92 and Aus$5.68 and earnings of as much as Aus$449.4 million.
Alcobra Pharma to conduct an IPO projecting to raise US$27.3 million. A pharmaceutical firm in Israel is in the process of developing oral medication that reduce the side effects of the treatment of attention deficit hyperactivity disorder.
